Keyword: Orexigen Therapeutics
It’s been a painful few years for Orexigen Therapeutics in the obesity arena, and the company is finally ready to bow out.
Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.
Obesity drugmaker Orexigen may be game for a sale. The question is, is anyone game for a buy?
The FDA issued its first untitled letter of the year for promotional infractions to scold Orexigen Therapeutics for infractions in a Contrave TV ad.
Industry lobbying group PhRMA has cleared its decks of nearly two dozen members as it tries to distance itself from those companies most likely to catch heat over drug pricing practices.
Orexigen has its go-it-alone marketing plans for Contrave figured out. Problem is, they won’t result in growth for quite a while.
Orexigen lost its Contrave marketing partner Takeda last month. Now, the drugmaker has terminated its second try at an FDA-mandated heart safety study, putting the drug at risk of FDA action.